Antibiotic residue and toxicity assessment of wastewater during the pharmaceutical production processes

Chemosphere ◽  
2021 ◽  
pp. 132837
Author(s):  
JiaJia Xue ◽  
Dandan Lei ◽  
Xiumei Zhao ◽  
Yaru Hu ◽  
Shijie Yao ◽  
...  
Processes ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. 67
Author(s):  
Stefanie Hering ◽  
Nico Schäuble ◽  
Thomas M. Buck ◽  
Brigitta Loretz ◽  
Thomas Rillmann ◽  
...  

Increasing regulatory demands are forcing the pharmaceutical industry to invest its available resources carefully. This is especially challenging for small- and middle-sized companies. Computer simulation software like FlexSim allows one to explore variations in production processes without the need to interrupt the running process. Here, we applied a discrete-event simulation to two approved film-coated tablet production processes. The simulations were performed with FlexSim (FlexSim Deutschland—Ingenieurbüro für Simulationsdienstleistung Ralf Gruber, Kirchlengern, Germany). Process visualization was done using Cmap Tools (Florida Institute for Human and Machine Cognition, Pensacola, FL, USA), and statistical analysis used MiniTab® (Minitab GmbH, Munich, Germany). The most critical elements identified during model building were the model logic, operating schedule, and processing times. These factors were graphically and statistically verified. To optimize the utilization of employees, three different shift systems were simulated, thereby revealing the advantages of two-shift and one-and-a-half-shift systems compared to a one-shift system. Without the need to interrupt any currently running production processes, we found that changing the shift system could save 50–53% of the campaign duration and 9–14% of the labor costs. In summary, we demonstrated that FlexSim, which is mainly used in logistics, can also be advantageously implemented for modeling and optimizing pharmaceutical production processes.


2009 ◽  
Vol 98 (4) ◽  
pp. 1487-1498 ◽  
Author(s):  
Hui Zhang ◽  
Zhuangde Jiang ◽  
J.Y. Pi ◽  
H.K. Xu ◽  
R. Du

Author(s):  
Stephan Dorn

Art 55 UPCA implements Art 34 TRIPs. The rule on the burden of proof contained in Art 54 UPCA would have the effect that the owner of a patent for a procedure (procedural patent) must assert and prove the use of the procedure carried out by the alleged infringer. This would, in many cases, cause great difficulty for the patentee since he may not be able at all or only with a tremendous amount of effort to validly draw a conclusion of the procedure used in production. This applies especially to chemical and pharmaceutical production processes protected by a patent. For those cases, Art 55(1) UPCA provides for a reversal of proof. Each identical product, in the absence of proof to the contrary, will be deemed to have been obtained by the patented process. The reversal of proof exclusively relates to the procedure which was used in the production of the product. In other respects, the burden of proof, according to Art 54 UPCA, remains unchanged. Therefore, also under Art 55(1) UPCA, the patent owner must prove that his product is new and that the accused product is identical to that new product.


2013 ◽  
Vol 58 ◽  
pp. 344-368 ◽  
Author(s):  
Ravendra Singh ◽  
Andy Godfrey ◽  
Björn Gregertsen ◽  
Frans Muller ◽  
Krist V. Gernaey ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document